Abstract:To develop a new interventional oncology technique, "radiofrequency hyperthermia (RFH)-enhanced herpes simplex virus thymidine kinase (GFP/HSV-TK)/ganciclovir (GCV) gene therapy of cholangiocarcinoma." Luciferase/mCherry-labeled cholangiocarcinoma cells and 24 mice with subcutaneously implanted cholangiocarcinoma cells were treated by: (i) a combination of green fluorescent protein (GFP)/HSV-TK/plasmid gene transfection followed by RFH and ganciclovir exposure; (ii) gene therapy alone; (iii) RFH alone; and (iv) phosphate-buffered saline (PBS) to serve as a control (6 mice per group). Cell viabilities were quantified by MTS assay. Bioluminescent optical imaging and transcutaneous ultrasound imaging were used to follow up the tumor growth over 2 weeks. For in-vivo technical validation of the new technique, pigs in two groups received either intrabiliary delivery of GFP/HSV-TK/plasmid using a needle-integrated balloon catheter flowed by RFH enhancement (n = 6) or gene delivery only (n = 6). GFP signal in bile duct walls were quantified by optical imaging.The non- parametric Mann-Whitney U test was used for statistical comparison of variables. MTS assay demonstrated the lowest cell proliferation in combination therapy compared with three control groups (24.0 ± 5.3% vs 41.9 ± 6.4% vs 72.0 ± 9.0% vs 100%, p<0.001). GFP optical imaging confirmed that GFP/HSV-TK gene expression peaked at day 2 after gene transfection. Bioluminescent optical imaging demonstrated the decreased bioluminescence signals in tumors of combination therapy, compared with other control groups (0.71 ± 0.16 vs 1.46 ± 0.21 vs 2.10 ± 0.27 vs 2.36 ± 0.28, p<0.001). Ultrasound imaging showed the smallest tumor volumes of the combination therapy group, compared with other groups (0.90 ± 0.21 VS 1.61 ± 0.21 VS 2.22 ± 0.25 VS 2.50 ± 0.30, p<0.001). optical imaging confirmed higher GFP expression in the bile ducts with RFH enhancement (signal to noise ratio: 1.28 ± 0.61 VS 0.49 ± 0.31, P<0.05). It is feasible to use intratumoral RFH to enhance GFP/HSV-TK/plasmid gene expression and HSV-TK/GCV gene therapy of cholangiocarcinomas.This concept may pave a new avenue for managing pancreatobiliary malignancies.(supported by an NIH RO1EBO12467)

Transgenic mice expressing inhibin α-subunit promoter (inhα)/Simian Virus 40 T-antigen (Tag) transgene as a model for the therapy of granulosa cell-derived ovarian cancer

Molecular Imaging-Monitored Radiofrequency Hyperthermia-Enhanced Intratumoral Herpes Simplex Virus-Thymidine Kinase Gene Therapy for Rat Orthotopic Ovarian Cancer.

Abstract No. 576 Orthotopic Ovarian Cancer: Molecular Imaging-Monitored Radiofrequency Hyperthermia-Enhanced Intratumoral Herpes Simplex Virus-Thymidine Kinase (HSV-TK) Gene Therapy

Epithelial Ovarian Cancer: Feasibility of Image-Guided Intratumoral Radiofrequency Hyperthermia-Enhanced Direct Gene Therapy

A genetically engineered ovarian cancer mouse model based on fallopian tube transformation mimics human high-grade serous carcinoma development

A Novel Treatment Strategy for Ovarian Cancer Based on Immunization Against Zona Pellucida Protein (ZP) 3

Intrabiliary Radiofrequency Heating-Enhanced Direct Intratumoral GFP/HSV-TK Gene Therapy of Cholangiocarcinoma: A Preclinical Study on Mice and Pigs

Development of Intraperitoneally Transplantated Human Ovarian Carcinoma Model with Immune Reconstruction in Severe Combined Immunodeficient Mice

Genetically Defined Syngeneic Mouse Models of Ovarian Cancer as Tools for the Discovery of Combination Immunotherapy

Transcriptomic Profiling of Gene Expression Associated with Granulosa Cell Tumor Development in a Mouse Model

Enhanced Efficiency and Specificity of Ovarian Cancer Gene Therapy in Rats with A Novel Nonviral Gene Delivery System (ge7) Via Intraovarian Artery Perfusion Approach

Treatment of Intraperitoneal Implanted Human Ovarian Carcinoma of Nude Mice by Angiostatin Gene and Chemotherapy In Vivo

Tumor-directed Gene Therapy in Mice Using a Composite Nonviral Gene Delivery System Consisting of the Piggybac Transposon and Polyethylenimine

Efficacy of Lentivirus-Mediated and Muc1 Antibody-Targeted Vp22-Tk/Gcv Suicide Gene Therapy for Ovarian Cancer

New construction of an animal model for the orthotopic transplantation of an ovarian tumor

Antitumor effect of chondroitin sulfate-coated ternary granulocyte macrophage-colony-stimulating factor plasmid complex for ovarian cancer

Transcriptional Control of the MUC16 Promoter Facilitates Follicle-Stimulating Hormone Peptide-Conjugated Shrna Nanoparticle-Mediated Inhibition of Ovarian Carcinoma in Vivo

Production of Transgenic Mice Expressing Tumor Virus A under Ovarian-Specific Promoter 1 Control Using Testis-Mediated Gene Transfer

Efficient Inhibition of Ovarian Cancer Growth and Prolonged Survival by Transfection with a Novel Pro-Apoptotic Gene, hPNAS-4, in a Mouse Model

Efficient Inhibition of Intraperitoneal Ovarian Cancer Growth in Nude Mice by Liposomal Delivery of Short Hairpin RNA Against STAT3

Genetically modified mouse models addressing gonadotropin function